Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma

Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma

Despite the promising efficacy of atezolizumab plus bevacizumab (atezo/bev), some patients with unresectable hepatocellular carcinoma (HCC) experience disease progression. This retrospective study, which included 154 patients, aimed to evaluate predictors of treatment efficacy of atezo/bev for unres...

Full description

Bibliographic Details
Main Authors: Norikazu Tanabe, Issei Saeki, Yuki Aibe, Takashi Matsuda, Tadasuke Hanazono, Maiko Nishi, Isao Hidaka, Shinya Kuwashiro, Shogo Shiratsuki, Keiji Matsuura, Maho Egusa, Natsuko Nishiyama, Tsuyoshi Fujioka, Daiki Kawamoto, Ryo Sasaki, Tatsuro Nishimura, Takashi Oono, Takuro Hisanaga, Toshihiko Matsumoto, Tsuyoshi Ishikawa, Takahiro Yamasaki, Taro Takami
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Cancers
Subjects:
hepatocellular carcinoma
atezolizumab
bevacizumab
alpha-fetoprotein
des-gamma-carboxy prothrombin
immune checkpoint inhibitor
Online Access:https://www.mdpi.com/2072-6694/15/11/2927

Similar Items

Similar Items